Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

ISIN: ES0167733015 | Ticker: ORY | LEI: 95980063R15RDF29DK13
Sector: Health CareSub-Industry: Biotechnology
Country: Spain

About Oryzon Genomics S.A.

Company Description

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

Year founded

2000

Served area

Europe + North America

Headcount

43

Headquarters

Carrera de San Jeronimo 15, 28014 Madrid – Spain

Filings & Publications

2019

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2018

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2017

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2016

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2015

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2014

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2013

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2012

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

ES0167733015

LEI

95980063R15RDF29DK13

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Bolsa de Madrid

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.